Ivonescimab+Chemo

Phase 2Small molecule

YYang Fan, MD

Ivonescimab+Chemo is one of 7 small molecule programs targeting Resectable NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Resectable NSCLCNot yet recruiting

Resectable NSCLCPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Resectable NSCLC

#DrugCompanyPhaseTrials

Fabhalta

Regeneron

Phase 2

1 2

Opdivo

Bristol-Myers Squibb

Phase 2

1 3

Libtayo

Regeneron

Phase 2

1 4

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 5

Platinum Doublet

Regeneron

Phase 2

1 6

Immunochemotherapy Combined With Antiangiogenic

IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 2

1 7

Ivonescimab+Chemo

YYang Fan, MD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Resectable NSCLC

NCT07086326

Clinical

Trials by Indication[1]

Resectable NSCLC1 trial

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

Not yet recruiting·YYang Fan, MD·Phase 2·NCT07086326·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ivonescimab+Chemo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ivonescimab+Chemo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ivonescimab+Chemo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yang Fan, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYang Fan, MD

Ivonescimab+Chemo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Resectable NSCLC1 trial

References

Drug Info

Quick Facts

Related News